Zepbound vs. Rybelsus
Zepbound and Rybelsus share a GLP-1 receptor agonist mechanism but have different applications. Zepbound also includes a GIP receptor agonist. Zepbound focuses on chronic weight management, delivering substantial weight loss, while Rybelsus is an oral option for type 2 diabetes, providing moderate weight benefits alongside HbA1c reductions. Both share nausea as a common side effect, with Rybelsus also linked to gastrointestinal discomfort. Zepbound’s cost is $1,125/month, while Rybelsus costs $875/month. Neither drug currently faces shortages.
Enhances the effects of both incretin hormones. GIP improves insulin sensitivity and enhances fat metabolism, while GLP-1 reduces appetite, delays gastric emptying, and promotes insulin secretion, making it effective for blood sugar control and weight loss.
Common Side Effects
Nausea, vomiting, diarrhea, decreased appetite, and indigestion
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, diarrhea, vomiting, and abdominal pain.
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions